Virus-like particles as HIV-1 vaccines

Reviews in Medical Virology

Volumn 15, Issue 2, 2005, Pages 75-88

  Doan, Linh X ^a   Li, Min ^a   Chen, Changyi ^a   Yao, Qizhi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CAPSID PROTEIN; CHIMERIC PROTEIN; CHOLERA TOXIN; DNA VACCINE; E1A PROTEIN; EPITOPE; FURIN; GAG PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LIVE VACCINE; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PLASMID VECTOR; POL PROTEIN; PROTEIN P27; PROTEIN P55; PROTEIN VP1; REV PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN; VIRUS PROTEIN; VIRUS PROTEIN X; VPR PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; BACULOVIRUS EXPRESSION SYSTEM; CELL SURFACE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG POTENCY; DRUG PURIFICATION; DRUG SAFETY; DRUG SYNTHESIS; EXPRESSION VECTOR; GENE CONSTRUCT; GENE MUTATION; GENETIC RECOMBINATION; GENETIC RISK; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOSTIMULATION; MEDICAL INFORMATION; MOLECULE; MUCOSAL IMMUNITY; NONHUMAN; REVERTANT; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS; VIRAL GENE THERAPY; VIRUS PARTICLE; YEAST ARTIFICIAL CHROMOSOME;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; ANTIGEN PRESENTATION; BACULOVIRIDAE; DENDRITIC CELLS; HIV ANTIBODIES; HIV-1; HUMANS; MICROSCOPY, ELECTRON; PLASMIDS; SACCHAROMYCES CEREVISIAE; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 14844300825     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.449     Document Type: Review

References (123)

1. Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat Med 2003; 9: 867-873.
2. Ellenberger D, Li B, Smith J, et al. Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG DNA vaccine for expression of multiple immunogenic forms. Virology 2004; 319: 118-130.
3. Ellenberger DL, Li B, Lupo LD, et al. Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development. Virology 2002; 302: 155-163.
4. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292: 69-74.
5. Mwau M, Cebere I, Sutton J, et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004; 85: 911-919.
6. Bertley FM, Kozlowski PA, Wang SW, et al. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol 2004; 172: 3745-3757.
7. de Bruyn G, Rossini AJ, Chiu YL, et al. Safety profile of recombinant canarypox HIV vaccines. Vaccine 2004; 22: 704-713.
8. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004; 55: 355-372.
9. Patterson LJ, Malkevitch N, Venzon D, et al. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 2004; 78: 2212-2221.
10. Vajdy M, Gardner J, Neidleman J, et al. Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles. J Infect Dis 2001; 184: 1613-1616.
11. Cruz LJ, Iglesias E, Aguilar JC, et al. A comparative study of different presentation strategies for an HIV peptide immunogen. Bioconjug Chem 2004; 15: 112-120.
12. Nehete PN, Gambhira R, Nehete BP, Sastry KJ. Dendritic cells enhance detection of antigen-specific cellular immune responses by lymphocytes from rhesus macaques immunized with an HIV envelope peptide cocktail vaccine. J Med Primatol 2003; 32: 67-73.
13. Pauza CD, Trivedi P, Wallace M, et al. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci USA 2000; 97: 3515-3519.
14. Chenciner N, Randrianarison-Jewtoukoff V, Delpeyroux F, et al. Enhancement of humoral immunity to SIVenv following simultaneous inoculation of mice by three recombinant adenoviruses encoding SIVenv/poliovirus chimeras, Tat and Rev. AIDS Res Hum Retroviruses 1997; 13: 801-806.
15. Dumais N, Patrick A, Moss RB, Davis HL, Rosenthal KL. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J Infect Dis 2002; 186: 1098-1105.
16. Moss RB, Diveley J, Jensen FC, Gouveia E, Carlo DJ. Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA. J Hum Virol 2001; 4: 39-43.
17. Burton DR, Desrosiers RC, Doms RW, et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004; 303: 316.
18. Trinvuthipong C. Thailand's prime-boost HIV vaccine phase III. Science 2004; 303: 954-955.
19. McNeil JG, Johnston MI, Birx DL, Tramont EC. Policy rebuttal. HIV vaccine trial justified. Science 2004; 303: 961.
20. Nelson K. Thai HIV vaccine trial prompts angry exchanges. Lancet 2004; 363: 299.
21. Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5: 233-236.
22. Cohen J. HIV/AIDS. Vaccine results lose significance under scrutiny. Science 2003; 299: 1495.
23. Cohen J. Clinical research. A setback and an advance on the AIDS vaccine front. Science 2003; 300: 28-29.
24. Cohen J. Disappointing data scuttle plans for large-scale AIDS vaccine trial. Science 2002; 295: 1616-1617.
25. Wang CJ, Chen PJ, Wu JC, Patel D, Chen DS. Small-form hepatitis B surface antigen is sufficient to help in the assembly of hepatitis delta virus-like particles. J Virol 1991; 65: 6630-6636.
26. Lowe RS, Brown DR, Bryan JT, et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis 1997; 176: 1141-1145.
27. Pumpens P, Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 2001; 44: 98-114.
28. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004; 4: 46-54.
29. Frazer I. Vaccines for papillomavirus infection. Virus Res 2002; 89: 271-274.
30. Breitburd F, Coursaget P. Human papillomavirus vaccines. Semin Cancer Biol 1999; 9: 431-444.
31. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982; 298: 347-350.
32. McAleer WJ, Buynak EB, Maigetter RZ, et al. Human hepatitis B vaccine from recombinant yeast. Nature 1984; 307: 178-180.
33. Berkower I, Raymond M, Muller J, Spadaccini A, Aberdeen A. Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120. Virology 2004; 321: 75-86.
34. Netter HJ, Woo WP, Tindle R, Macfarlan RI, Gowans EJ. Immunogenicity of recombinant HBsAg/HCV particles in mice pre-immunised with hepatitis B virus-specific vaccine. Vaccine 2003; 21: 2692-2697.
35. Evans TG, Bonnez W, Rose RC, et al. A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 2001; 183: 1485-1493.
36. Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93: 284-292.
37. Stanley MA. Progress in prophylactic and therapeutic vaccines for human papillomavirus infection. Expert Rev Vaccines 2003; 2: 381-389.
38. Zhang LF, Zhou J, Chen S, et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 2000; 18: 1051-1058.
39. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-1651.
40. Campbell S, Vogt VM. Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1. J Virol 1995; 69: 6487-6497.
41. Campbell S, Rein A. In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain. J Virol 1999; 73: 2270-2279.
42. Campbell S, Fisher RJ, Towler EM, et al. Modulation of HIV-like particle assembly in vitro by inositol phosphates. Proc Natl Acad Sci USA 2001; 98: 10875-10879.
43. Morikawa Y, Goto T, Sano K. In vitro assembly of human immunodeficiency virus type 1 Gag protein. J Biol Chem 1999; 274: 27997-28002.
44. Buonaguro L, Buonaguro FM, Tornesello ML, et al. High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res 2001; 49: 35-47.
45. Gheysen D, Jacobs E, de Foresta F, et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 1989; 59: 103-112.
46. Gottlinger HG, Sodroski JG, Haseltine WA. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1989; 86: 5781-5785.
47. Bergmann C, Stohlmann SA, McMillan M. An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein. Eur J Immunol 1993; 23: 2777-2781.
48. Niedrig M, Gelderblom HR, Pauli G, et al. Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides. J Gen Virol 1994; 75: 1469-1474.
49. Mammano F, Ohagen A, Hoglund S, Gottlinger HG. Role of the major homology region of human immunodeficiency virus type 1 in virion morphogenesis. J Virol 1994; 68: 4927-4936.
50. Wagner R, Demi L, Fliessbach H, Wanner G, Wolf H. Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles. Virology 1994; 200: 162-175.
51. Wagner R, Deml L, Schirmbeck R, et al. Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles. Virology 1996; 220: 128-140.
52. Tobin GJ, Li GH, Fong SE, Nagashima K, Gonda MA. Chimeric HIV-1 virus-like particles containing gp120 epitopes as a result of a ribosomal frameshift elicit Gag- and SU-specific murine cytotoxic T-lymphocyte activities. Virology 1997; 236: 307-315.
53. O'Reilly DR, Miller LK, Luckow VA. Baculovirus Expression Vectors - A Laboratory Manual. W.H. Freeman: London, 1992.
54. Yamshchikov GV, Ritter GD, Vey M, Compans RW. Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology 1995; 214: 50-58.
55. Yao Q, Vuong V, Li M, Compans RW. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity. Vaccine 2002; 20: 2537-2545.
56. Yao Q, Kuhlmann FM, Eller R, Compans RW, Chen C. Production and characterization of simian-human immunodeficiency virus-like particles. AIDS Res Hum Retroviruses 2000; 16: 227-236.
57. Vzorov AN, Tentsov I, Grigor'ev VB, et al. Formation of virus-like particles by HIV-1 Gag proteins, expressed by a recombinant vaccinia virus. Mol Biol (Mosk) 1990; 24: 1666-1674.
58. Vzorov AN, Compans RW. Assembly and release of SIV env proteins with full-length or truncated cytoplasmic domains. Virology 1996; 221: 22-33.
59. Luo L, Li Y, Yong Kang C. Budding and secretion of HIV Gag-Env virus-like particles from recombinant human adenovirus infected cells. Virus Res 2003; 92: 75-82.
60. Oliver SG, Mc CS, Holm C, et al. Biochemical and physiological studies of the yeast virus-like particle. J Bacteriol 1977; 130: 1303-1309.
61. Adams SE, Dawson KM, Gull K, Kingsman SM, Kingsman AJ. The expression of hybrid HIV:Ty virus-like particles in yeast. Nature 1987; 329: 68-70.
62. Sakuragi S, Goto T, Sano K, Morikawa Y. HIV type 1 Gag virus-like particle budding from spheroplasts of Saccharomyces cerevisiae. Proc Natl Acad Sci USA 2002; 99: 7956-7961.
63. Tsunetsugu-Yokota Y, Morikawa Y, Isogai M, et al. Yeast-derived human immunodeficiency virus type 1 p55(gag) virus-like particles activate dendritic cells (DCs) and induce perform expression in Gag-specific CD8(+) T cells by cross-presentation of DCs. J Virol 2003; 77: 10250-10259.
64. Buge SL, Ma HL, Amara RR, et al. Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge. AIDS Res Hum Retroviruses 2003; 19: 891-900.
65. Wyatt LS, Earl PL, Liu JY, et al. Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component. AIDS Res Hum Retroviruses 2004; 20: 645-653.
66. Smith JM, Amara RR, McClure HM, et al. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques. AIDS Res Hum Retroviruses 2004; 20: 654-665.
67. Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol 2003; 11: 438-444.
68. Brautigam S, Snezhkov E, Bishop DH. Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein. Virology 1993; 192: 512-524.
69. Zhou J, Stenzel DJ, Sun XY, Frazer IH. Synthesis and assembly of infectious bovine papillomavirus particles in vitro. J Gen Virol 1993; 74: 763-768.
70. Dale CJ, Liu XS, De Rose R, et al. Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. Virology 2002; 301: 176-187.
71. Greenstone HL, Nieland JD, de Visser KE, et al. Chimeric papillomavirus virus-like particles elicit anti-tumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 1998; 95: 1800-1805.
72. Liu XS, Abdul-Jabbar I, Qi YM, Frazer IH, Zhou J. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Virology 1998; 252: 39-45.
73. Ikuta K, Morita C, Nakai M, Yamamoto N, Kato S. Defective human immunodeficiency virus (HIV) particles produced by cloned cells of HTLV-I-carrying MT-4 cells persistently infected with HIV. Jpn J Cancer Res 1988; 79: 418-423.
74. Shioda T, Shibuta H. Production of human immunodeficiency virus (HIV)-like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV. Virology 1990; 175: 139-148.
75. Wagner R, Deml L, Wolf H. Polyvalent, recombinant HIV-1 virus-like particles: novel HIV-1 vaccine strategies. Antibiot Chemother 1994; 46: 48-61.
76. Buonaguro L, Racioppi L, Tornesello ML, et al. Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. Antiviral Res 2002; 54: 189-201.
77. Deml L, Kratochwil G, Osterrieder N, et al. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Virology 1997; 235: 10-25.
78. Deml L, Schirmbeck R, Reimann J, Wolf H, Wagner R. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Virology 1997; 235: 26-39.
79. Nixon DF, Huet S, Rothbard J, et al. An HIV-1 and HIV-2 cross-reactive cytotoxic T-cell epitope. Aids 1990; 4: 841-845.
80. Gotch FM, Nixon DF, Alp N, McMichael AJ, Borysiewicz LK. High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropositive individuals. Int Immunol 1990; 2: 707-712.
81. Wilk T, Pfeiffer T, Bosch V. Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product. Virology 1992; 189: 167-177.
82. Haffar O, Garrigues J, Travis B, et al. Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J Virol 1990; 64: 2653-2659.
83. Morikawa Y, Barsov E, Jones I. Legitimate and illegitimate cleavage of human immunodeficiency virus glycoproteins by furin. J Virol 1993; 67: 3601-3604.
84. Johnston PB, Dubay JW, Hunter E. Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells. J Virol 1993; 67: 3077-3086.
85. Yang C, Spies CP, Compans RW. The human and simian immunodeficiency virus envelope glycoprotein transmembrane subunits are palmitoylated. Proc Natl Acad Sci USA 1995; 92: 9871-9875.
86. Bugelski PJ, Maleeff BE, Klinkner AM, Ventre J, Hart TK. Ultrastructural evidence of an interaction between Env and Gag proteins during assembly of HIV type 1. AIDS Res Hum Retroviruses 1995; 11: 55-64.
87. Freed EO, Martin MA. Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix. J Virol 1995; 69: 1984-1989.
88. Freed EO, Martin MA. The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J Biol Chem 1995; 270: 23883-23886.
89. Guo L, Lu X, Kang SM, et al. Enhancement of mucosal immune responses by chimeric influenza HA/ SHIV virus-like particles. Virology 2003; 313: 502-513.
90. Yao Q. Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. Res Initiat Treat Action 2003; 8: 20-21.
91. Novak M, Moldoveanu Z, Schafer DP, Mestecky J, Compans RW. Murine model for evaluation of protective immunity to influenza virus. Vaccine 1993; 11: 55-60.
92. Jefferys R. HIV-specific immune responses key to speed of disease progression. AIDSMAP 2004.
93. Veazey RS, Shattock RJ, Pope M, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9: 343-346.
94. Notka F, Stahl-Hennig C, Dittmer U, Wolf H, Wagner R. Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies. Vaccine 2000; 18: 291-301.
95. Shibata R, Igarashi T, Haigwood N, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999; 5: 204-210.
96. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999; 283: 857-860.
97. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-126.
98. Jennes W, Vuylsteke B, Borget MY, et al. HIV-specific T helper responses and frequency of exposure among HIV-exposed seronegative female sex workers in Abidjan, Cote d'Ivoire. J Infect Dis 2004; 189: 602-610.
99. Klenerman P, Zinkernagel RM. Of mice and men: cytotoxic T cells and AIDS pathogenesis. AIDS Read 1999; 9: 474-480.
100. Madden LJ, Zandonatti MA, Flynn CT, et al. CD8+ cell depletion amplifies the acute retroviral syndrome. J Neurovirol 2004; 10(Suppl. 1): 58-66.
101. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 2004; 4: 199-210.
102. Paliard X, Liu Y, Wagner R, et al. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res Hum Retroviruses 2000; 16: 273-282.
103. Wagner R, Deml L, Schirmbeck R, Reimann J, Wolf H. Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development. Behring Inst Mitt 1994; 95: 23-34.
104. Belyakov IM, Derby MA, Ahlers JD, et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci USA 1998; 95: 1709-1714.
105. Heeney J, Akerblom L, Barnett S, et al. HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates. Immunol Lett 1999; 66: 189-195.
106. Michel ML, Mancini M, Sobczak E, et al. Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV-hepatitis B surface antigen particles. Proc Natl Acad Sci USA 1988; 85: 7957-7961.
107. Takamura S, Niikura M, Li TC, et al. DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration. Gene Ther 2004; 11: 628-635.
108. Gold D. Vaccine approaches currently in development. Body Posit 1998; 11: 34-35.
109. Jaffray A, Shephard E, van Harmelen J, et al. Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice. J Gen Virol 2004; 85: 409-413.
110. Stratov I, DeRose R, Purcell DF, Kent SJ. Vaccines and vaccine strategies against HIV. Curr Drug Targets 2004; 5: 71-88.
111. Billich A. AIDSVAX VaxGen. Curr Opin Investig Drugs 2004; 5: 214-221.
112. Marsac D, Loirat D, Petit C, Schwartz O, Michel ML. Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles. J Virol 2002; 76: 7544-7553.
113. Kang SM, Yao Q, Guo L, Compans RW. Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B. J Virol 2003; 77: 9823-9830.
114. Michel ML, Mancini M, Riviere Y, Dormont D, Tiollais P. T- and B-lymphocyte responses to human immunodeficiency virus (HIV) type 1 in macaques immunized with hybrid HIV/hepatitis B surface antigen particles. J Virol 1990; 64: 2452-2455.
115. Fausch SC, Da Silva DM, Kast WM. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res 2003; 63: 3478-3482.
116. Moron VG, Rueda P, Sedlik C, Leclerc C. In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J Immunol 2003; 171: 2242-2250.
117. Moron G, Rueda P, Casal I, Leclerc C. CD8alpha-CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules. J Exp Med 2002; 195: 1233-1245.
118. Castelli J, Thomas EK, Gilliet M, Liu YJ, Levy JA. Mature dendritic cells can enhance CD8+ cell non-cytotoxic anti-HIV responses: the role of IL-15. Blood 2004; 103: 2699-2704.
119. Carbonneil C, Aouba A, Burgard M, et al. Dendritic cells generated in the presence of granulocyte-macrophage colony-stimulating factor and IFN-alpha are potent inducers of HIV-specific CD8 T cells. Aids 2003; 17: 1731-1740.
120. Huang XL, Fan Z, Zheng L, et al. Priming of human immunodeficiency virus type 1 (HIV-1 )-specific CD8+ T cell responses by dendritic cells loaded with HIV-1 proteins. J Infect Dis 2003; 187: 315-319.
121. Heath WR, Carbone FR. Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunology 2001; 1: 126-134.
122. Zhang R, Li M, Chen C, Yao Q. SHIV virus-like particles bind and activate human dendritic cells. Vaccine 2004; In Press.
123. Yao Q, Zhang R, Guo L, Li M, Chen C. The cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine. J Immunol 2004; 173: 1951-1958.